Glutamate is the primary excitatory amino acid neurotransmitter in the human brain. It is important in synaptic plasticity, learning, and development. Its activity at the synaptic cleft is carefully balanced by receptor inactivation and glutamate reuptake. When this balance is upset, excess glutamate can itself become neurotoxic.

The neurotoxic properties of glutamate were first demonstrated in 1957 by Lucas and Newhouse, who showed that systemic administration of glutamate to infant mice caused retinal degeneration. Over the last 4 decades, a direct correlation between the neuroexcitatory and neurotoxic properties of glutamate has been linked to activation of excitatory amino acid receptors. This overactivation leads to an enzymatic cascade of events ultimately resulting in cell death.

Regulation of synaptic transmission and glutamate levels in the synaptic cleft is performed by glutamate transporters. Glutamate transport is a sodium- and potassium-coupled process that is capable of concentrating intracellular glutamate up to 10,000-fold compared with the extracellular space. These transporters are located throughout the human central nervous system as well as other tissues. Recent physiologic studies provide evidence that glutamate transporters keep synaptic concentrations of glutamate low enough to prevent receptor desensitization and/or excitotoxicity. New insights into the biology of these transporters suggest that their dysfunction may contribute to neurologic disease.

HUMAN GLUTAMATE TRANSPORTERS

Both neurons and astroglia are capable of high-affinity, sodium-dependent glutamate transport. To date, 5 high-affinity, sodium-dependent glutamate transporters have been cloned from mammalian and human tissue: astrocyte-specific glutamate transporter (GLAST [excitatory amino acid transporter 1 (EAAT1)]), glutamate transporter 1 (GLT-1 [excitatory amino acid transporter 2 (EAAT2)]), excitatory amino acid carrier 1 (EAAC1 [excitatory amino acid transporter 3 (EAAT3)]), excitatory amino acid transporter 4 (EAAT4), and excitatory amino acid transporter 5 (EAAT5) (Table).

Immunohistochemical studies have revealed that EAAT1 and EAAT2 are localized primarily in astrocytes, while EAAT3 and EAAT4 are distributed in neuronal membranes. Detailed immunogold studies have further delineated the localization of glutamate transporters to certain subcellular compartments. The neuronal transporters EAAT3 and EAAT4 appear to be localized to plasma membranes in a perisynaptic distribution. The greatest density of these transporter proteins appears to be at the edge of postsynaptic densities, rather than within the synaptic cleft. To date, most immunolocalization studies have further indicated that the neuronal transporters are localized in a somatodendritic fashion on postsynaptic spines and somas. They are rarely found presynaptically. In fact, to date, the only localization of glutamate transporters presynaptically has been on presynaptic inhibitory γ-aminobutyric acid (GABA) terminals.

In a similar fashion, the astroglial glutamate transporters also have a polarized distribution. Both EAAT1 and EAAT2 are
localized to astroglial membranes that immediately oppose synaptic cleft regions of the neuropil (Figure 1).  
In mammalian studies, it has been demonstrated that EAAT1 is highly expressed in the molecular layer of the cerebellum and moderates activity in the hippocampus, superior colliculus, and substantia gelatosa of the spinal cord. In contrast, EAAT2 expression is generally high throughout all brain regions and the spinal cord but is largely absent from white matter tracts; EAAT3 is selectively enriched in neurons of the hippocampus, cerebellum, and basal ganglia; EAAT4 is largely confined to the soma and dendrites of the Purkinje cells of the cerebellum; EAAT5 is located in retinal ganglion cells (Table).

Thus, the anatomic analysis of the molecular subtypes of glutamate transporters suggests that glutamate inactivation may be either postsynaptic or on astroglial membranes. In fact, in the hippocampus, a region of intense glutamatergic innervation, there is little evidence for presynaptic or postsynaptic inactivation by neuronal transporters. Rather, all available data suggest that astroglial transporters are the predominant physiologic pathway for synaptic inactivation of glutamate in the forebrain.

NEUROSCIENTIFIC STUDY OF GLUTamate TRANSPORTER DYSFUNCTION

How does glutamate transporter dysfunction lead to neurotoxic effects and subsequent neurologic sequence? The relationship between loss of glutamate transporters and enhancement of extracellular glutamate levels with subsequent neurotoxic effects has been well established. Knockout mice deficient in the glutamate transporter subtypes have been developed. They yield a variety of phenotypes, including seizures, loss of motor coordination, and disturbances in amino acid metabolism.  

Multiple mechanisms have been postulated to cause motor neuron degeneration in sporadic and familial forms of ALS, including excitotoxic effects, oxidative injury, cytoskeletal abnormalities, and autoimmunity. It is likely that multiple primary insults result in the common phenotype of ALS. Evidence for glutamate contributing to motor neuron degeneration in ALS initially came from several studies that suggested that cerebrospinal fluid glutamate levels may be elevated in patients with sporadic ALS. These earlier studies reported that motor cortex and spinal cord tissue glutamate levels were decreased 30% to 45% in patients with ALS. These alterations in extracellular and tissue glutamate may in fact reflect alterations in glutamate transport. This hypothesis was subsequently evaluated and confirmed through the use of membrane preparations of postmortem tissue from ALS patients and controls. In those studies, a significant loss of high-affinity, sodium-dependent glutamate transport was found in ALS. Detailed studies were performed to examine molecular subtypes of glutamate transport in ALS. These revealed that up to 60% to 70% of patients with sporadic ALS have a 30% to 90% loss of the EAAT2 protein, in both motor cortex and spinal cord. The loss of EAAT2 appears to be specific to these regions.
in most but not all patients. This loss of EAAT2 protein cannot be attributed to cell death since there is no significant astroglial loss in ALS.

Parallel with human studies, a number of laboratories have been investigating the biology of the EAAT2 protein. Functional studies have determined that the EAAT2 transporter is the most abundant glutamate transporter in the brain, both at the protein level and functionally. Up to 95% of all tissue glutamate transport appears to be through the EAAT2 glutamate transporter.

What is the relevance of a loss of EAAT2? Both in vitro and in vivo studies have documented that antisense knockdown or pharmacologic inhibition of a glutamate transporter leads to neuronal degeneration, especially of the motor neurons. In adult animals, antisense knockdown of EAAT2, analogous to astrocytes in adult animals, antisense knockdown or pharmacologic inhibition of a glutamate transporter in the brain, both at the protein level and functionally. Up to 95% of all tissue glutamate transport appears to be through the EAAT2 glutamate transporter.

What could cause the loss of an astroglial glutamate transporter in a regional manner in sporadic ALS? Two possible mechanisms for loss of glutamate transporter proteins in ALS have been suggested. First, studies in ALS have revealed the presence of truncated RNA species in patients with sporadic ALS. Detailed analyses have revealed that ALS is associated with a large increase in multiple aberrant RNA species that code for truncated versions of the EAAT2 protein. Although 1 or 2 of these species can occasionally be seen in control specimens, ALS is unique in both the abundance, using vigorous quantitative methods to assess these truncated RNA species, and the large number of different truncated RNA species in individual patients. Studies of some of these truncated species indicate that they have a dominant-negative effect on the EAAT2 protein and provide a mechanism for explaining a loss of EAAT2 protein in patients.

Second, evidence suggesting a link between free radical formation and glutamate transporter dysfunction comes from a mouse model of ALS. Mutations of superoxide dismutase (SOD1) have been found in approximately 10% of patients with familial ALS. Transgenic mice overexpressing mutant SOD1 genes display a slowly progressive motor neuron disease resembling ALS. The mechanism for the neurotoxic effects associated with mutant SOD1 is not yet known, but evidence supports the gain of a toxic property. In addition, recent studies have documented that mutant SOD1 by itself can induce oxidative damage to the EAAT2 protein that could also provide an alternate means for loss of glutamate transport in ALS patients. Regardless of the mechanism, the loss of EAAT2 glutamate transporter may contribute to a reduction in glutamate uptake with subsequent overstimulation of glutamate receptors, resulting in neurotoxic effects.

As described above, glutamate transporters may be a target for these toxic effects. In fact, recent studies of SOD1 transgenic mice show a marked loss of GLT1 (EAAT2) in the spinal cord as well as a loss of functional glutamate transport. Thus, the loss of glutamate transport is seen both in familial models of ALS and in sporadic disease.

Alzheimer Disease

The neurodegeneration in AD is characterized by synaptic and neuronal loss with plaque and tangle formation. Abnormal expression or pro-

©2001 American Medical Association. All rights reserved.
cessing of growth-associated proteins in the central nervous system may play a role in the process, leading to damage and neurodegeneration. Amyloid precursor protein has been implicated as being important in the pathogenesis of AD. Recently, it has been demonstrated that abnormal processing of amyloid precursor protein may be associated with the deficient functioning of the glutamate transporter system. In fact, a fragment of β-amyloid (Aβ), the central constituent of neuritic plaques in AD, inhibited tritium-labeled glutamate uptake in cultured astrocytes. Since reactive oxygen species are mediators of Aβ toxic effects and uptake inhibition by Aβ was prevented by antioxidants, it is conceivable that, among other effects, Aβ produces glutamate transporter oxidation and dysfunction.35

Stroke/Ischemia

Aberrant function of glutamate transport plays an essential role in the excitotoxic neurodegeneration that occurs in models of cerebral ischemia. As mentioned in the introduction, there is a tenfold higher concentration of glutamate within cells compared with the outside environment. The energy and ion gradient necessary to maintain this state fail under ischemic conditions. In fact, numerous in vitro studies have documented the actual reversal of glutamate transporter: glutamate that runs down its gradient from within cells to swamp the extracellular environment. The energy and ion gradient necessary to maintain this state fail under ischemic conditions. In fact, numerous in vitro studies have documented the actual reversal of glutamate transporter: glutamate that runs down its gradient from within cells to swamp the extracellular environment with large amounts of intracellular glutamate.34-36

Changes in glutamate transporter expression are seen with cerebral ischemia in animal models and human tissue. Astrocyte-specific glutamate transporter expression was increased in the penumbra 72 hours following ischemia in an animal model. This suggests that a compensatory increase in the activity of glutamate transporters may accompany pathological changes after ischemic injury.37 The paucity of GLAST and GLT1 in specific regions of the hippocampus may account for the vulnerability of these neurons to an ischemic insult.38

Transient hypoxic-ischemic injury in a neonatal pig model demonstrates reduced levels of GLT1 and EAAC1 at 24 hours of recovery. Thus, astroglial and neuronal injury were found to occur rapidly in the newborn striatum, with early gliodegeneration and glutamate transporter abnormalities contributing to neurodegeneration.39

Selective cell vulnerability to neonatal hypoxia-ischemia may be attributed to loss of glutamate transporter subtypes. Changes in GLAST and EAAT4 (a Purkinje cell-specific transporter) in the cerebellum of hypoxic human neonates, examined postmortem, may account for the well-described vulnerability of Purkinje cells to hypoxic injury.40

While the regulation of the different transporter subtypes in varying anatomic regions and ischemic zones is still being studied, these changes are in response to and a result of neurotoxic effects.

Epilepsy

The family of glutamate transporter proteins may also be participants in certain models of epilepsy, although their role may be dependent more on their participation in the central nervous system metabolism than on their role as regulators of external glutamate concentrations. In knockout mice, a reduction in the glutamate transporter GLT1 results in lethal spontaneous seizures. By 6 weeks of age, 50% of animals die. Pathologically, some of the mice that lack the GLT1 transporter show destruction of neurons in the hippocampus, a region found to be important in the generation of seizure disorders.41 Interestingly, developmental studies indicate that this time point is critical for the development of excitatory synapses. The loss of a predominant glutamate transporter in the neonatal brain, GLT1, therefore may be critical for normal synaptogenesis and prevention of seizures. In that regard, it is interesting that in adult animals, the loss of GLT1 leads not to seizures but, as described above, motor neuron degeneration. Thus, alterations in transporter expression may have pathophysiological consequences for the cell types in which they are expressed, their ultrastructural localization, and the developmental timing at which insults occur. Interestingly, GLAST and EAAC1 knockout mice, while not normal, do not develop seizures.

In acquired models of epilepsy in which seizures are induced using a variety of pharmacological models, the data are somewhat conflicting. In a study of mRNA and protein expression using fully kindled rats, few changes in GLT or GLAST were found in the hippocampus.42 Conversely, when the glutamate receptor agonist kainate was used to induce seizures, EAAC1 mRNA and protein levels were decreased in the rat hippocampus, GLT1 mRNA and protein levels were increased, and GLAST mRNA levels were increased.43

Recent experimental studies have provided a new means by which glutamate transporters may contribute to epilepsy. Infusing antisense oligonucleotides into the ventricles of adult rats with the molecular knockdown of EAAC1, a highly expressed hippocampal transporter, can produce episodic seizures in these animals.44 Initial studies suggest that this effect occurs not through alterations of an extracellular glutamate, but rather through perturbations of the neurotransmitter GABA. The EAAC1 transporter is highly localized to GABA pre-synaptic terminals, and preliminary studies suggest that its dysfunction can alter neurotransmitter GABA metabolism (unpublished results from our laboratory). This alteration results in a loss of pre-synaptic release of GABA, diminishing inhibition. A disturbance of this metabolic function of glutamate transporters could underlie some pathophysiologic pathways of epilepsy.

In patients undergoing anterior temporal lobectomy for refractory seizures, brain tissue from the anterior temporal lobe did not reveal changes in the level of expression of the glutamate transporters EAAT1 and EAAT2.45 In human studies of hippocampal sclerosis, however, EAAT2 and EAAT3 levels are increased in areas were neurons are spared and reduced in regions of neuronal cell loss.46

Taken together, these data suggest that alterations in glutamate transporters in both human tissue and animal models may play a role...
in the generation and propagation of ictal activity. Determining whether these changes are the primary cause of induction of seizures or a compensatory response to neuronal injury requires further study.

APPLICATIONS FOR DIAGNOSIS

Currently, the World Federation of Neurology criteria are used to establish a diagnosis of ALS. These criteria are based upon history and physical findings suggesting loss of upper and lower motor neurons and electrophysiologic evidence of denervation. Unfortunately, the diagnosis is often not established until late in the disease. New approaches to support the diagnosis are therefore welcome.

Lin et al detected EAAT2 mRNA splice mutants in the cerebrospinal fluid of 66% of patients with sporadic ALS, but none in patients with nonneurologic disease or in controls with other diseases. Importantly, these splice mutants were also detectable early in the course of the disease. Although currently reliable qualitative and quantitative polymerase chain reaction methods might be difficult to perform in clinical laboratories, the collection of cerebrospinal fluid could be an adjunct to the current methods of diagnosis in the future. The identification of markers contributing to disease activity by conventional lumbar puncture may eventually lead to earlier diagnosis and institution of treatment for this devastating disease.

COMMENT

Glutamate neurotoxicity has long been known to contribute to the pathogenesis of neurologic disorders such as stroke, epilepsy, and ALS. The finding that glutamate transporter dysfunction plays a role in these disorders is a more recent discovery. Given that glutamate is ubiquitous in the central nervous system, glutamate transporter dysfunction may play a role in other neurologic disorders as well. At the present time, several drugs used to treat neurologic disorders have activity at the glutamatergic synapse. Glutamate receptor antagonists have been tried in stroke in an attempt to limit the size and severity of ischemic insults. Riluzole is currently approved for use in the treatment of ALS and is believed to act by preventing the release of glutamate. The antiepileptic drug topiramate acts as an antagonist of the AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)/kainate subtype of the glutamate receptor.

Recently, a number of proteins have been identified that can modulate glutamate transporter subtypes. Future manipulation of these proteins may also provide novel therapeutic means to regulate glutamate transport and afford therapeutic benefit.

Given what we have learned from the therapeutic applications of compounds active at glutamatergic synapses, manipulation of glutamate transporters may also prove promising. Future directions could include the development of glutamate transporter agonists to increase glutamate uptake from the synaptic cleft.

The use of gene therapy to deliver genes of interest to particular cell types is a rapidly expanding field. Gene therapy may be implemented to overexpress glutamate transporters in target cells. Glutamate transport from the extracellular space could be facilitated by increasing the number of glutamate transporters in neurons and glia.

The biology of free radical formation and its relationship to disease has garnered a great deal of attention recently. This has led to the pharmaceutical use of antioxidants to treat a host of different disorders. Antioxidants may be of use in preventing damage to glutamate transporters, offering an exciting approach to preventing glutamate accumulation in the synapse.

The study of these transporters as they relate to neurologic disease in humans is in its infancy. Understanding their biology will be critical in developing strategies for manipulating them in the future.

Accepted for publication April 26, 2000.

Corresponding author and reprints: Jeffrey D. Rothstein, Department of Neurology, Johns Hopkins University, Meyer 6-109, 600 N Wolfe St, Baltimore, MD 21287 (e-mail: jrothst@jhmi.edu).

REFERENCES


18. Peghini P, Janzen J, Stoffel W. Glutamate transporter 


22. Bristol LA, Rothstein JD. Glutamate transporter 


41. Akbar MT, Torn R, Donbalt NC, Levy LM, Mel-